Board of Directors
Eight directors with extensive experiences in science and medicine, industry
and venture capital currently serve on the Argos Board to provide strategic
direction to the company.
|Clint G. Dederick, Jr.,
||Chairman & CEO,
|Chairman of the Board
|Hubert Birner, Ph.D., M.B.A.
|B. Jefferson (Jeff) Clark, M.B.A.
|Eli Gilboa, Ph.D.
|Michel Gréco, M.B.A.
|Philip R. (Phil) Tracy, J.D.
|Brian J. Underdown, Ph.D.
|Sander van Deventer, M.D., Ph.D.
Clint G. Dederick, Jr., M.B.A.
Chairman of the Board, CEO and President
Clint Dederick brings over 30 years of experience in the pharmaceutical
and biotechnology industries to Argos Therapeutics. He has served as chairman
of the board for 3 years since the company’s inception. Dederick was
group director, venture projects, of Senmed Medical Ventures for 15 years
prior to becoming CEO and president of Argos in 2002. He also served on the
boards of several companies during his tenure with Senmed. Prior to joining
Senmed, Dederick worked with Praxis Biologics, Inc., Seragen, Inc., and Collaborative
Research, Inc. He also worked with Eli Lilly & Co., where he was engaged
with a variety of domestic and international assignments over a period of
ten years. Dederick’s academic background includes an undergraduate
degree from the University of Delaware in biology and chemistry, and a
M.B.A. from the University of Virginia Darden School.
return to top
Hubert Birner, Ph.D. M.B.A.
Hubert Birner is a partner with TVM and joined that organization in October
2000. He is vice chairman of the board of Direvo Biotech AG (Cologne).
Previously, he held senior management positions at AstraZeneca's agribusiness
(now known as Syngenta) as Head of Business Development, Europe, and Director
of Marketing, Germany. Birner joined AstraZeneca from McKinsey & Company's
European Health Care and Pharmaceutical practice. As a consultant, he gained
extensive experience in R&D management, marketing & sales as well
as joint venture structuring and business development. Birner was also
an Assistant Professor for biochemistry at the Ludwig-Maximilians-University
in Munich. In this capacity, he directed various research projects for
pharmaceutical companies. He holds an M.B.A. from Harvard Business School
and a summa cum laude doctoral degree in biochemistry from Ludwig-Maximilians-University
Munich. His doctoral thesis was honored with the Hoffmann-La Roche prize
for outstanding fundamental research in metabolic diseases.
return to top
B. Jefferson (Jeff) Clark, M.B.A.
B. Jefferson Clark co-founded The Aurora Funds, Inc. (Aurora) in 1994 and
is currently General Partner responsible for life science investments in
Aurora’s three existing funds, which encompass in excess of $72 million.
Prior to forming Aurora, Clark worked in development and external affairs
for Duke University. Clark has extensive strategic planning and operational
experience and has overseen more than a dozen life science investments since
1995. He presently serves on the boards of seven of Aurora’s life
science portfolio companies, including Insect Biotechnology, Inc., Argos
Inc., Norak Biosciences, VetCentric, Peracom, TriVirix International, and
United Emergency Services, assisting in the strategic direction of each.
Clark also serves on the board of directors of the Duke Comprehensive Cancer
Center and the Council for Entrepreneurial Development. Clark holds a B.S.
in mechanical engineering from Duke University and an M.B.A. from the Fuqua
School of Business at Duke University.
return to top
Eli Gilboa, Ph.D.
Eli Gilboa is scientific founder and chairman of the scientific advisory
board and serves as acting chief scientific officer for Argos Therapeutics.
Gilboa is a co-inventor of the Company’s core therapeutic vaccine technology;
an expert in immunology, molecular biology and immunotherapy; and an early
pioneer in the gene therapy field. He is currently Director of the Center
for Genetic and Cellular Therapies at Duke University Medical Center. He
is also a Joseph and Dorothy Beard Professor of Experimental Surgery and
Immunology, Departments of Surgery and Immunology, Duke University Medical
Center. Gilboa served as an Associate Member of the Sloan Kettering Institute
for Cancer Research Molecular Biology Program from 1986 to 1993. He was Assistant
Professor in the Department of Molecular Biology at Princeton University
from 1980 to 1986. He graduated in 1971 from Hebrew University, Jerusalem,
Israel with a B.S. in biochemistry. Gilboa received his Ph.D. in molecular
biology at the Weizmann Institute, Rehovot, Israel in 1977.
return to top
Michel Gréco has vast experience in healthcare field and vaccine
research. He is a board member of several public and private companies
institutions, and advisor to the World Health Organization.
Gréco began his career with Theraplix, a pharmaceutical subsidiary
of the French Group Rhône Poulenc in 1968. In 1975, he was appointed
Vice President for Commercial Operations, France and International. In 1982,
Gréco moved to Rhône Poulenc’s Health Division as Vice
President Strategy, in charge of Corporate Marketing. In 1987, he joined
another Rhône Poulenc subsidiary, "Institut Mérieux Human
Health", a leading vaccine company based in Lyon France. There, he was
appointed Deputy General Manager in 1988. Gréco has participated in
the successive acquisitions of Pasteur Vaccins (the Vaccine arm of Institut
Pasteur) and Connaught Laboratories (in the United States and Canada) and
became Vice President Europe of the new company (Pasteur Mérieux Connaught).
Gréco was deputy CEO and member of the Board of Aventis Pasteur until
January 2003. Since leaving Aventis, Gréco has been a board member
of Powderject (UK) and was instrumental in its acquisition by Chiron.
Gréco is presently a board member of three public companies traded
on the NASDAQ, a board member of three private companies, 3 international
institutions and is an advisor to World Health Organization (WHO) for vaccine
research. Gréco has been president of two French professional associations:
the Groupement pour l'Elaboration et la Réalisation de Statistiques
(GERS), a market research association, 1980-1983, the Club Interpharmaceutique
(CIP), an association in the area of pharmaceutical distribution, 1986-1994,
as well as president of the European Vaccine Manufacturers (EVM), 1994-1998
and President of the Biological Committee of the International Federation
of Pharmaceutical Industry Associations (1999-2002).
Gréco has written several articles on the vaccine field and has participated
in many international conferences. He recently authored a chapter of “New
Generation Vaccines,” 3rd edition. He has also taught several French
Gréco holds a master’s degree from Institut d'Etudes Politiques
de Paris (1965) and an M.B.A. from the University of Western Ontario, Richard
IVEY Business School, Canada (1968).
return to top
Richard Meadows was the lead partner in a $30.5 million USD investment in
TARGEGEN, a San Diego-based company focusing on the mechanism of edema formation
in AMI and solid tumors in cancer. There, he shared leadership in financing
with William Blair. Meadows has been appointed to four Boards of biotechnology
companies, including Argos Therapeutics, THERION Biologics, MOLECULAR MINING
Meadows joined CDP Capital Technology Ventures in 2003 as a Venture Advisor,
assisting partners in overseeing and managing their North American investments,
as well as making new investments in promising biomedical companies. Prior
to that, he was president and CEO of the first Canadian start-up in wound
care. He started with a Series-A round of $3.5 million of VC money, and,
in collaboration with the Medical Research Council of Canada (MRC), Investments
Partnerships Canada, Industry Canada and the Department of Foreign Affairs
and International Trade (DFAIT), Meadows created the Life Sciences Research
Investments Initiative in 1997.
Meadows has facilitated, developed and wrote strategic plans for the following:
a spin-off of the NRC focused on Gap-Junction modulation (PharmaGap (GAP
on the TSX Venture Exchange); a new Canadian R&D facility for Cheil
Jedang Pharma of Seoul, Korea; a Canadian subsidiary for a multinational
firm (with annual sales of 4+ billion FFr); a major diversification effort
by a large healthcare firm into the OTC market; a world-class research
institute (Institute of Biomedical Engineering of the University of Toronto);
Toronto Hospital Research Division.
Additionally, Meadows is a 2004 Board member of the Canadian Biotechnology
Human Resources Council; a 2000 appointed representative of the SPEQ, to
the Board of BIORTHEX, Inc. He was appointed, Chairman, Audit Committee;
a 1999-2000 Member of the Board of Directors, DERMACOR Inc.; a 1995 - 1999
Member of the Board & Human Resources Committee, BIORTHEX, Inc. Montreal,
QC; a 1997-1998 Consultant to The Business Development Office, the Medical
Research Council of Canada; a 1999- 2000 Business Advisor, EXELLA, Life
Sciences Equities, Inc. a VC fund established to invest in genomics projects.
also an elected member of the Drug Information Association, New York Academy
of Sciences, North American Planning Conference, and the Canadian Healthcare
return to top
Philip R. Tracy, J.D.
Philip R. Tracy was formerly the president and CEO of Burroughs Wellcome
Co., a major research-based pharmaceutical company with $1.2 billion
in sales and 5,000 employees. Tracy has served on the boards of directors
of the Pharmaceutical Research and Manufacturers Association of America
and the Nonprescription Drug Manufacturers Association. He also currently
serves as chairman of the board of visitors for the Duke University Medical
Center. Through 1996, Tracy was a member of the board of visitors for
the University of North Carolina at Chapel Hill. He is presently Of Counsel
with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P.
Tracy is also a venture partner of Intersouth Partners and currently
serves on the boards of directors of three Intersouth portfolio companies,
two public and one private. He received his B.A. from University of Nebraska
and his J.D. from George Washington University.
return to top
Brian J. Underdown, Ph.D.
Brian J. Underdown is currently vice-president, science and technology
at MDS Capital Corp. Underdown is also president and chief operation officer
of University Medical Discoveries Inc. (UMDI), jointly founded by MDS Capital
and the Canadian Medical Discoveries Fund. Prior to joining MDS Capital,
he held various senior-level positions in the commercial and academic sectors
including assistant vice-president of research, at Pasteur Merieux Connaught.
Before that, he was the associate dean of research at McMaster University,
Faculty of Health Sciences and the University of Toronto Faculty of Medicine.
His primary research interests have been in the field of mucosal immunology
and vaccine development. Underdown attended McGill University where he
graduated with a B.S. in honors chemistry and a Ph.D. in immunology and
undertook post-doctoral studies at Washington University.
return to top
Sander van Deventer,
Sander van Deventer is Professor of Gastroenterology at the Academic Medical
Center in Amsterdam. Dr. van Deventer has held numerous academic appointments
and has been the principle clinical investigator for several clinical trials.
He has served on a number of regulatory and pharmaceutical industry scientific
advisory boards and has been an advisor to the Food and Drug Administration.
Dr. van Deventer received his M.D. and Ph.D. from the University of Amsterdam.
return to top